Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and autoimmune diseases on people’s lives is why we’re here

Research and development

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

An immunotherapy platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ immunotherapy has the potential to treat many disease areas, including cancer.

Highlights

Nykode Therapeutics to Present at the H.C. Wainwright 28th ...

Read More
09 September 2026

Nykode Therapeutics ASA – Private Placement Completed

Read More
27 August 2026

Nykode Therapeutics ASA – Contemplated Private Placement

Read More
27 August 2026

Nykode Therapeutics receives draft recommendation from Secretariat of Tax ...

Read More
26 August 2026

Nykode Therapeutics reports Q2 2026 Financial Results

Read More
26 August 2026

Nykode Therapeutics – Invitation to Q2 2026 Financial Results ...

Read More
21 August 2026

Nykode Therapeutics Receives New U.S. Patent Strengthening Intellectual Property ...

Read More
20 August 2026

Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and ...

Read More
22 July 2026

Nykode Therapeutics reports Q1 2026 Financial Results

Read More
27 May 2026